Table 5.
Hazard ratios for overall survival (OS) in the breast cancer patients with anthracycline‐based chemotherapy
| Variable | Univariate | P [Link] | Multivariate | P [Link]‡ |
|---|---|---|---|---|
| HR (95% CI)[Link] | HR (95% CI)[Link]‡ | |||
| Age (≥45 years vs <45 years) | 1.003 (0.764–1.316) | 0.983 | ||
| Menopausal status (postmenopausal vs premenopausal) | 0.870 (0.662–1.143) | 0.318 | ||
| XPC Ala499Val (CT+TT vs CC) | 1.227 (0.922–1.633) | 0.160 | ||
| XPC Lys939Gln (AC+CC vs AA) | 0.717 (0.536–0.960) | 0.025 | 0.620 (0.389–0.987) | 0.044 |
| First‐degree family history of breast cancer (yes vs no) | 1.064 (0.778–1.454) | 0.699 | ||
| Tumor size (>4 cm vs ≤4 cm) | 0.818 (0.667–1.002) | 0.053 | ||
| Histology (DIC/LIC vs others) | 1.064 (0.778–1.454) | 0.699 | ||
| Lymph node metastases (metastases vs non‐metastases) | 1.441 (1.013–2.049) | 0.042 | 1.585 (1.013–2.475) | 0.043 |
| ER status (positive vs negative) | 0.966 (0.734–1.272) | 0.805 | ||
| PR status (positive vs negative) | 1.074 (0.815–1.414) | 0.613 | ||
| Her‐2 status (positive vs negative) | 0.920 (0.692–1.221) | 0.562 | ||
| BRCA1 status (positive vs negative) | 0.997 (0.728–1.365) | 0.983 | ||
| BRCA2 status (positive vs negative) | 0.899 (0.674–1.199) | 0.469 |
†P‐values, odds ratios (OR), and 95% confidence intervals (CI) were assessed using univariate Cox regression analysis. ‡BRCA1, breast cancer type 1 susceptibility protein; BRCA2, breast cancer type 2 susceptibility protein; Her‐2, human epidermal growth factor receptor; DIC, ductal invasive carcinoma; ER, estrogen receptor; HR, hazards ratio; LIC, lobular invasive carcinoma; p53, tumor protein 53; PR, progesterone receptor.